Associations between abnormal vitamin D metabolism pathway function and non‑small cell lung cancer

Ge,Nan; Chu,Xiu‑Mei; Xuan,Yun‑Peng; Ren,Dun‑Qiang; Wang,Yongjie; Ma,Kai; Gao,Hui‑Jiang; Jiao,Wen‑Jie

doi:10.3892/ol.2017.7162

Associations between abnormal vitamin D metabolism pathway function and non‑small cell lung cancer

Authors:
- Nan Ge
- Xiu‑Mei Chu
- Yun‑Peng Xuan
- Dun‑Qiang Ren
- Yongjie Wang
- Kai Ma
- Hui‑Jiang Gao
- Wen‑Jie Jiao
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/ol.2017.7162
Pages: 7538-7544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a type of malignant tumor derived from the respiratory system, which is the leading cause of cancer‑associated mortality worldwide, of which ~80% of cases are attributable to non‑small cell lung cancer (NSCLC). A previous study demonstrated that 1α,25‑Dihydroxyvitamin D3 (1α,25(OH)2D3), derived from the vitamin D metabolic pathway contributes an antitumor effect. Aberrant expression of the essential enzyme encoding genes, Cytochrome P450 Family 27 Subfamily A Member 1 (CYP27A1), Cytochrome P450 Family 27 Subfamily B Member 1 (CYP27B1), and Cytochrome P450 Family 24 Subfamily A Member 1 (CYP24A1) may be associated with lung cancer. However, a lack of evidence exists concerning the association between CYP27A1, CYP27B1, CYP24A1 expression and NSCLC. The aim of the present study was to investigate the functions of CYP27A1, CYP27B1 and CYP24A1 expression in NSCLC. Lung cancer tissue and para‑carcinoma control tissue were collected from patients with NSCLC. Reverse transcription‑quantitative polymerase chain reaction was applied to analyze CYP27A1, CYP27B1 and CYP24A1 mRNA expression in lung cancer tissues. An association analysis was performed between the aforementioned metabolic enzymes and patients with NSCLC age, gender, tumor node metastasis (TNM) stage, pathological type, differentiation and prognosis. CYP27B1 and CYP24A1 mRNA were upregulated in NSCLC compared with controls (P<0.05). However, no significant differences in CYP27A1 expression were observed between NSCLC and control. In addition, CYP24A1 expression was not associated with age, sex, smoking or TNM stage, but was associated with pathological type, differentiation and prognosis (P<0.05). CYP27B1 expression was significantly associated with TNM stage, differentiation, and prognosis, but not age, sex, smoking or pathological type. In conclusion, CYP27B1 and CYP24A1 may be considered as independent prognostic factors of NSCLC and may be novel therapeutic targets to assist clinical diagnosis, treatment and prognosis of the disease.

View Figures

View References

1	Gudala S, Khan U, Kanungo N, Bandaru S, Hussain T, Parihar M, Nayarisseri A and Mundluru HP: Identification and pharmacological analysis of high efficacy small molecule inhibitors of EGF-EGFR interactions in clinical treatment of non-small cell lung carcinoma: A computational approach. Asian Pac J Cancer Prev. 16:8191–8196. 2015. View Article : Google Scholar : PubMed/NCBI
2	Xia M, Duan ML, Tong JH and Xu JG: MiR-26b suppresses tumor cell proliferation, migration and invasion by directly targeting COX-2 in lung cancer. Eur Rev Med Pharmacol Sci. 19:4728–4737. 2015.PubMed/NCBI
3	Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, et al: Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: A phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 10:1745–1753. 2015. View Article : Google Scholar : PubMed/NCBI
4	Guerrera F, Tabbò F, Bessone L, Maletta F, Gaudiano M, Ercole E, Annaratone L, Todaro M, Boita M, Filosso PL, et al: The Influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) biobank. PLoS One. 11:e01451002016. View Article : Google Scholar : PubMed/NCBI
5	Tai CJ, Wang CK, Tai CJ, Tzao C, Lien YC, Hsieh CC, Hsieh CI, Wu HC, Wu CH, Chang CC, et al: Evaluation of safety and efficacy of salvage therapy with sunitinib, docetaxel (Tyxane) and cisplatinum followed by maintenance vinorelbine for unresectable/metastatic nonsmall cell lung cancer: Stage 1 of a simon 2 stage clinical trial [Corrected]. Medicine (Baltimore). 94:e23032015. View Article : Google Scholar : PubMed/NCBI
6	Robinson AG, Young K, Balchin K, Owen T and Ashworth A: Reasons for palliative treatments in stage III non-small-cell lung cancer: What contribution is made by time-dependent changes in tumour or patient status? Curr Oncol. 22:399–404. 2015. View Article : Google Scholar : PubMed/NCBI
7	Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, Kido K, Iwakami S, Tominaga S and Takahashi K: Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig. 54:14–19. 2016. View Article : Google Scholar : PubMed/NCBI
8	Kepka L and Socha J: PET-CT limitations in early stage non-small cell lung cancer: To whom more aggressive approach in radiotherapy and surgery should be directed? J Thorac Dis. 7:1887–1890. 2015.PubMed/NCBI
9	Piotrowska A, Wierzbicka J, Nadkarni S, Brown G, Kutner A and Żmijewski MA: Antiproliferative activity of double point modified analogs of 1,25-dihydroxyvitamin D₂ against human malignant melanoma cell lines. Int J Mol Sci. 17:pii: E76. 2016. View Article : Google Scholar
10	Aguirre M, Manzano N, Salas Y, Angel M, Díaz-Couselo FA and Zylberman M: Vitamin D deficiency in patients admitted to the general ward with breast, lung, and colorectal cancer in buenos aires, argentina. Arch Osteoporos. 11:42016. View Article : Google Scholar : PubMed/NCBI
11	Wen Y, Da M, Zhang Y, Peng L, Yao J and Duan Y: Alterations in vitamin D signaling pathway in gastric cancer progression: A study of vitamin D receptor expression in human normal, premalignant, and malignant gastric tissue. Int J Clin Exp Pathol. 8:13176–13184. 2015.PubMed/NCBI
12	Vashi PG, Edwin P, Popiel B and Gupta D: The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer. BMC Cancer. 15:10122015. View Article : Google Scholar : PubMed/NCBI
13	Christakos S, Dhawan P, Verstuyf A, Verlinden L and Carmeliet G: Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 96:365–408. 2016. View Article : Google Scholar : PubMed/NCBI
14	Khayatzadeh S, Feizi A, Saneei P and Esmaillzadeh A: Vitamin D intake, serum Vitamin D levels, and risk of gastric cancer: A systematic review and meta-analysis. J Res Med Sci. 20:790–796. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hibler EA, Molmenti Sardo CL, Dai Q, Kohler LN, Anderson Warren S, Jurutka PW and Jacobs ET: Physical activity, sedentary behavior, and vitamin D metabolites. Bone. 83:248–255. 2016. View Article : Google Scholar : PubMed/NCBI
16	Huang Z, Yi X, Luo B, Zhu J, Wu Y, Jiang W, Chu H, Yang Z, Li S, Zhu H, et al: Induced sputum deposition improves diagnostic yields of pulmonary alveolar proteinosis: A clinicopathological and methodological study of 17 cases. Ultrastruct Pathol. 40:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ortakoylu MG, Iliaz S, Bahadir A, Aslan A, Iliaz R, Ozgul MA and Urer HN: Diagnostic value of endobronchial ultrasound-guided transbronchial needle aspiration in various lung diseases. J Bras Pneumol. 41:410–414. 2015.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
18	Yin K, You Y, Swier V, Tang L, Radwan MM, Pandya AN and Agrawal DK: Vitamin D protects against atherosclerosis via regulation of cholesterol efflux and macrophage polarization in hypercholesterolemic swine. Arterioscler Thromb Vasc Biol. 35:2432–2442. 2015. View Article : Google Scholar : PubMed/NCBI
19	Fedorova OV, Zernetkina VI, Shilova VY, Grigorova YN, Juhasz O, Wei W, Marshall CA, Lakatta EG and Bagrov AY: Synthesis of an endogenous steroidal na pump inhibitor marinobufagenin, implicated in human cardiovascular diseases, is initiated by CYP27A1 via bile acid pathway. Circ Cardiovasc Genet. 8:736–745. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gascon-Barré M, Demers C, Ghrab O, Theodoropoulos C, Lapointe R, Jones G, Valiquette L and Ménard D: Expression of CYP27A, a gene encoding a vitamin D-25 hydroxylase in human liver and kidney. Clin Endocrinol (Oxf). 54:107–115. 2001. View Article : Google Scholar : PubMed/NCBI
21	Adams JS and Hewison M: Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys. 523:95–102. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mast N, Lin JB and Pikuleva IA: Marketed drugs can inhibit cytochrome P450 27A1, a potential new target for breast cancer adjuvant therapy. Mol Pharmacol. 88:428–436. 2015. View Article : Google Scholar : PubMed/NCBI
23	Brożyna AA, Jochymski C, Janjetovic Z, Jóźwicki W, Tuckey RC and Slominski AT: CYP24A1 expression inversely correlates with melanoma progression: Clinic-pathological studies. Int J Mol Sci. 15:19000–19017. 2014. View Article : Google Scholar : PubMed/NCBI
24	Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G and Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 58:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
25	Anderson MG, Nakane M, Ruan X, Kroeger PE and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 57:234–240. 2006. View Article : Google Scholar : PubMed/NCBI
26	Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF and Chen TC: 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol. 81:135–140. 2002. View Article : Google Scholar : PubMed/NCBI
27	Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, Wang Z, Thomas DG, Giordano TJ, Lin L, et al: CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res. 17:817–826. 2011. View Article : Google Scholar : PubMed/NCBI
28	Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T, Albanes D, Mucci LA, Giovannucci E and Kraft P: Breast and Prostate Cancer Cohort Consortium Group: Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the national cancer institute breast and prostate cancer cohort consortium. Cancer. 121:1949–1956. 2015. View Article : Google Scholar : PubMed/NCBI
29	Lee WR, Ishikawa T and Umetani M: The interaction between metabolism, cancer and cardiovascular disease, connected by 27-hydroxycholesterol. Clin Lipidol. 9:617–624. 2014. View Article : Google Scholar : PubMed/NCBI
30	Kong J, Xu F, Qu J, Wang Y, Gao M, Yu H and Qian B: Genetic polymorphisms in the vitamin D pathway in relation to lung cancer risk and survival. Oncotarget. 6:2573–2782. 2014. View Article : Google Scholar
31	Jacobs ET, Van Pelt C, Forster RE, Zaidi W, Hibler EA, Galligan MA, Haussler MR and Jurutka PW: CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res. 73:2563–2573. 2013. View Article : Google Scholar : PubMed/NCBI